Real World Solutions
Full spectrum of expertise in Market Access, Health Economics & Outcomes Research, and Real World Evidence (RWE)
Fact Sheet
HTA and Payer Submissions
Mar 09, 2026
IQVIA helps life sciences organizations secure timely, positive reimbursement decisions in Canada by guiding products from regulatory approval through Health Technology Assessment (HTA) and payer submissions. Drawing on deep expertise with Canada’s Drug Agency (CDA), INESSS, and more than 30 private payers, we build evidence‑driven strategies that demonstrate value, strengthen economic narratives, and align with payer decision‑making frameworks.
Our integrated approach combines real‑world evidence, proprietary Canadian data assets, advanced modelling, and end‑to‑end submission development. From pre‑submission planning and clinical evidence templates to pharmacoeconomic evaluations, budget impact analyses, and post‑submission support, we streamline every stage of the process to maximize reimbursement potential.
Organizations gain a one‑stop partner for robust HTA dossiers, compelling value propositions, and tailored payer engagement—helping ensure patients receive timely access to the therapies they need.